A general and powerful stage-wise testing procedure for differential expression and differential transcript usage
Background: Reductions in sequencing cost and innovations in expression quantification have prompted an emergence of RNA-seq studies with complex designs and data analysis at transcript resolution. These applications involve multiple hypotheses per gene, leading to challenging multiple testing problems. Conventional approaches provide separate top-lists for every contrast and false discovery rate (FDR) control at individual hypothesis level. Hence, they fail to establish proper gene-level error control, which compromises downstream validation experiments. Tests that aggregate individual hypotheses are more powerful and provide gene-level FDR control, but in the RNA-seq literature no methods are available for post-hoc analysis of individual hypotheses. Results: We introduce a two-stage procedure that leverages the increased power of aggregated hypothesis tests while maintaining high biological resolution by post-hoc analysis of genes passing the screening hypothesis. Our method is evaluated on simulated and real RNA-seq experiments. It provides gene-level FDR control in studies with complex designs while boosting power for interaction effects without compromising the discovery of main effects. In a differential transcript usage/expression context, stage-wise testing gains power by aggregating hypotheses at the gene level, while providing transcript-level assessment of genes passing the screening stage. Finally, a prostate cancer case study highlights the relevance of combining gene with transcript level results. Conclusion: Stage-wise testing is a general paradigm that can be adopted whenever individual hypotheses can be aggregated. In our context, it achieves an optimal middle ground between biological resolution and statistical power while providing gene-level FDR control, which is beneficial for downstream biological interpretation and validation.
- Downloaded 694 times
- Download rankings, all-time:
- Site-wide: 35,045
- In bioinformatics: 3,909
- Year to date:
- Site-wide: 122,503
- Since beginning of last month:
- Site-wide: 125,618
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!